Skip to content

Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates

Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates At-risk of Early-onset Bacterial Sepsis: a Multicentric, Randomized, Controlled, Non-inferiority Trial (the SAUNA Trial)

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06377397
Acronym
SAUNA
Enrollment
1500
Registered
2024-04-22
Start date
2024-04-15
Completion date
2028-04-14
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early-Onset Neonatal Sepsis, Preterm Birth, Preterm Premature Rupture of Membrane, PROM, Preterm (Pregnancy), Sepsis

Keywords

Prolonged rupture of membranes, Preterm premature rupture of membranes, Early-onset neonatal sepsis, Selective antibiotics, Non-inferiority trial

Brief summary

Preterm infants are born at less than 37 weeks of pregnancy. Sometimes a break or tear in the fluid filled bag that surrounds and protects the infant during pregnancy leads to an untimely birth. This state puts the infant at risk of serious condition called sepsis. Sepsis is a condition in which body responds inappropriately to an infection. Sepsis may progress to septic shock which can result in the loss of life. Doctors give antibiotics to treat sepsis. The goal of this research study is to find out: 1. Among neonates at risk of early-onset neonatal sepsis, whether a policy of administering antibiotics selectively to a subset of at-risk infants who later develop signs of sepsis is not inferior to administering antibiotics to all at-risk infants in the 1st week of life. 2. To find out if infants receiving selective antibiotics (as above) compared to those receiving antibiotics from birth (as above) require fewer antibiotic courses of 48 hours duration or more in the 1st week of life. 3. To find out whether infants receiving selective antibiotics (as above) compared to those receiving antibiotics from birth (as above) are significantly different with respect to a wide range of secondary outcomes (listed under Outcomes).

Detailed description

Sepsis is the major cause of neonatal mortality and early-onset neonatal sepsis (EONS) accounts for more than two-thirds of all cases of neonatal sepsis. Prolonged rupture of membranes (PROM) and preterm premature rupture of membranes (pPROM) are important risk factors of EONS. There is equipoise in the published literature whether antibiotics must be immediately initiated among all preterm neonates (\<35 weeks gestation) delivered following PROM or pPROM who are asymptomatic at birth or whether antibiotics can be selectively administered if and when the at-risk neonates become symptomatic. Among neonates \<35 weeks gestation born with PROM \>18 hours or pPROM and who are either asymptomatic or have no symptoms of sepsis at 4 hrs postnatally (P), is selectively administering antibiotics to neonates who later develop clinical sepsis \[I\] compared to administering antibiotics pre-emptively to all at-risk neonates \[C\] non-inferior with respect to the composite outcome of mortality and/or culture-positive sepsis and/or severe sepsis \[O\] within 7 days after enrolment \[T\] by an absolute margin of 7% \[E\] in a randomized controlled trial (S)? The trial will also have a superiority outcome: need for antibiotic treatment lasting greater than 48 hours within 7 days after enrolment. The absolute superiority margin will be 50%. The main objectives are as follows: 1. To determine whether antibiotics administered selectively to at-risk preterm neonates \[\<35 weeks gestation with prolonged rupture of membranes (PROM) or preterm premature rupture of membranes (pPROM)\] when they develop signs of sepsis compared to administering antibiotics from birth to all at-risk neonates is non-inferior with respect to the primary outcome of mortality or any episode of culture-positive sepsis or severe sepsis in the 1st week of life 2. To determine whether neonates receiving selective antibiotics (as above) compared to those receiving antibiotics from birth (as above) are superior with respect to the co-primary outcome of fewer antibiotic courses of 48 hours duration or more in the 1st week of life 3. To determine whether neonates receiving selective antibiotics (as above) compared to those receiving antibiotics from birth (as above) are significantly different with respect to a wide range of secondary outcomes (listed under Outcomes)

Interventions

DRUGAntibiotics

In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs. In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment

Sponsors

Lady Hardinge Medical College
CollaboratorOTHER_GOV
King George's Medical University
CollaboratorOTHER
Indira Gandhi Institute of Child Health
CollaboratorUNKNOWN
Institute of Obstetrics and Gynecology
CollaboratorUNKNOWN
Government Medical College, Chandigarh
CollaboratorOTHER
Pandit Bhagwat Dayal Sharma, PGIMS, Rohtak
CollaboratorOTHER
Government Medical College, Aurangabad
CollaboratorOTHER_GOV
King Edward Memorial Hospital, Mumbai
CollaboratorOTHER_GOV
Indian Council of Medical Research
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Project staff, nurses and resident doctors looking after the neonate will not be blinded. The assessment of the primary outcome will be performed by a blinded adjudicator, who is not involved in the recruitment and monitoring of subjects. A part of the case report form (CRF) containing relevant details of all episodes of sickness in the 1st week of life will be detached from the main form and will be sent to the blinded adjudicator. This part will be linked to the main form only by a unique identification number. No patient identifiers or allocation group will be mentioned on the part sent to the blinded adjudicator.

Intervention model description

Neonates will be randomized to 1 of the following groups: 1. Group 1: Intervention group (Selective antibiotic group) 2. Group 2: Comparison group (Universal antibiotic group)

Eligibility

Sex/Gender
ALL
Age
0 Hours to 4 Hours
Healthy volunteers
No

Inclusion criteria

* Gestational age of 26 to 34 weeks * Chronological age 4 hours * Have any one or both of the following risk factors of EONS: * Prolonged rupture of membranes \>18 hours * Pre-labour rupture of membranes \[as all subjects will be preterm, this is effectively pPROM\] * Are either asymptomatic or have no signs attributable to sepsis at 4 hours. This will be defined as absence of the following clinical signs or need for interventions mentioned below: 1. Apnea (Standard definition) requiring intervention at any time until enrolment. 2. Need for a fluid bolus or inotropic support at any time until enrolment. 3. Seizures or seizure-like activity at any time until enrolment. 4. Upper GI bleed in the absence of a history of ante-partum hemorrhage at any time until enrolment. 5. Pus from any site at any time until enrolment. 6. Need for CPAP \>6 cms of water with FiO2 \>35% at 6-8 hours OR need for CPAP £6 cms and FiO2 £35% but with increasing requirement of support\*\* 7. Chest Xray (if performed) with radiological features of pneumonia. 8. Need for intubation and mechanical ventilation. 9. Temperature \>37.5°C or \<36°C, unexplained by environmental causes 10. Feed intolerance \[bilious or bloodstained vomiting (or gastric residuals) or visibly distended abdomen or \>50% of the previous feed volume as gastric residuals\] 11. Lethargy or unarousability 12. Sclerema

Exclusion criteria

Subjects will be excluded if they have any 1 of the following: <!-- --> 1. Life-threatening congenital malformation 2. Severe perinatal asphyxia (Apgar score \<5 at 10 minutes or cord pH \<7.0) 3. Clinical chorioamnionitis# \[see definition below\] 4. Foul-smelling liquor 5. Multiple gestation 6. Received a dose of antibiotics 7. Positive amniotic fluid culture (if performed and available prior to randomization) 8. Treating neonatologist unwilling to enroll the patient in the trial on the grounds that the patient needs antibiotics. \-

Design outcomes

Primary

MeasureTime frameDescription
Composite of all-cause mortality and/or any episode of culture-positive sepsis and/or severe sepsis* within the 1st 7 days after randomizationWithin 1st 7 days after randomizationEither mortality due to any cause and/or an episode of culture-positive sepsis and/or severe sepsis. These outcomes will be measured within the 1st 7 days after randomization, which for all practical purposes, is equivalent to the 1st 7 days of life since participants will be randomized at about 4 hours of life. Hence, the duration expressed after randomization and of life will be used interchangeably for this outcome and other outcomes.
Need for intravenous antibiotics for ≥ 48 hours within the 1st 7 days after randomizationWithin 1st 7 days after randomizationRequirement for intravenous antibiotic courses whose duration is ≥ 48 hours with the onset of the course within the first 7 days after randomization. For all practical purposes, this would be equivalent to the 1st 7 days of life since participants will be randomized at about 4 hours of life.

Secondary

MeasureTime frameDescription
Episode of severe sepsis within 1st 7 days after randomizationWithin 1st 7 days after randomizationAny episode of severe sepsis during 1st 7 days after randomization. Severe sepsis be defined as clinical signs of sepsis AND either a positive blood culture or laboratory evidence of sepsis (either CRP OR Procalcitonin above the age-appropriate cut-off value OR any two of the CBC parameters outside the age-appropriate ranges OR chest x-ray suggestive of pneumonia) AND one or more of the following indices of severity \[Need for intubation and mechanical ventilation, Need for inotropes \>10 mic/kg/min dopamine or \>10 mic/kg/min dobutamine or adrenaline \> 0.05 mic/kg/min, Need for exchange transfusion, Need for platelet concentrates or FFP, Meningitis (defined as either CSF culture positive or Gram stain positive or Cell count \>25/microlitre or glucose \<25 mg/dl or protein \>180 mg/dl)\]
Composite of mortality/blood culture positive sepsis/severe sepsis within 1st 72 hours after randomizationWithin first 72 hour after randomizationEither mortality and/or blood culture-positive sepsis and/or severe sepsis
Individual components of composite outcome within 1st 72 hours after randomizationWithin 1st 72 hours after randomizationSeparately mortality, blood culture-positive sepsis or severe sepsis
Composite of mortality/blood culture positive sepsis/severe sepsis during hospital stayDuring hospital stay upto 100 days after randomizationEither mortality due to any cause and/or blood culture-positive sepsis and/or severe sepsis during hospital stay, with maximum duration of observation during hospital stay being capped at 100 days
Individual components of composite outcome during hospital stayDuring hospital stay upto 100 days after randomizationSeparately mortality, blood culture-positive sepsis or severe sepsis during hospital stay, with maximum duration of observation during hospital stay being capped at 100 days
Necrotizing enterocolitis, stage II-III by modified Bell's staging criteria during hospital stayDuring hospital stay upto 100 days after randomizationNecrotizing enterocolitis stage II-III by modified Bell's staging criteria during hospital stay, with maximum duration of observation during hospital stay being capped at 100 days after randomization
Composite of mortality/blood culture positive sepsis/severe sepsis during 1st 30 days after randomizationDuring 1st 30 days after randomizationEither all-cause mortality and/or blood culture-positive sepsis and/or severe sepsis during the 1st 30 days after randomization
Individual components of composite outcome during 1st 30 daysDuring 1st 30 days after randomizationSeparately, all-cause mortality, blood culture-positive sepsis or severe sepsis during the 1st 30 days after randomization
Necrotizing enterocolitis, stage II-III by modified Bell's staging criteriaDuring 1st 30 days after randomizationNecrotizing enterocolitis, stage II-III by modified Bell's staging criteria during the 1st 30 days after randomization
Sepsis-related mortality within 1st 72 hours after randomizationWithin 1st 72 hours after randomizationMortality due to sepsis within 1st 72 hours. The decision of the treating team will be recorded for attributing mortality to sepsis.
Sepsis-related mortality within 7 day after randomizationWithin 7 days after randomizationMortality due to sepsis within 7 days after randomization. The decision of the treating team will be recorded for attributing mortality to sepsis.
Sepsis-related mortality during hospital stay after randomizationDuring hospital stay upto 100 days after randomizationMortality due to sepsis during hospital stay. The decision of the treating team will be recorded for attributing mortality to sepsis.
Sepsis-related mortality during 1st 30 days after randomizationDuring 1st 30 days after randomizationMortality due to sepsis during 1st 30 days after randomization
Clinical sepsis within 1st 72 hours after randomizationWithin 1st 72 hours after randomizationEpisodes of clinical EONS (as per definition from a repertoire of clinical signs with normal lab parameters) within 1st 72 hours
Clinical sepsis within 7 days after randomizationWithin 7 days after randomizationEpisodes of clinical EONS (as per definition from a repertoire of clinical signs with normal lab parameters) within 7 days
Blood culture-positive sepsis of any severity within 1st 7 days after randomizationWithin 1st 7 days after randomizationBlood culture proven septicemia
Clinical sepsis within 1st 30 days after randomizationDuring 1st 30 days after randomizationEpisodes of clinical EONS (as per definition from a repertoire of clinical signs with normal lab parameters) within 1st 30 days of life
Episode of Probable EONS within 72 hours after randomizationWithin 72 hours after randomizationEpisode of Probable EONS \[as per definition from a repertoire of clinical signs, AND with abnormal age-appropriate values of one or more of TLC, ANC, CRP, PCT, chest x-ray suggestive of pneumonia AND with sterile blood culture\]
Episode of Probable EONS within 7 days after randomizationWithin 7 days after randomizationEpisode of Probable EONS \[as per definition from a repertoire of clinical signs, AND with abnormal age-appropriate values of one or more of TLC, ANC, CRP, PCT, chest x-ray suggestive of pneumonia AND with sterile blood culture\]
Episode of asymptomatic proven EONS within 72 hours after randomizationWithin 72 hours after randomizationEpisode of asymptomatic proven EONS \[asymptomatic but baseline blood culture positive with non-contaminant organism\]
Need for sepsis workup during 1st 72 hours after randomizationDuring 1st 72 hours after randomization\[Sepsis workup defined as one or more of CBC, CRP, Procalcitonin, blood culture\] during 1st 72 hours of life
Need for sepsis workup during 1st 7 days after randomizationDuring 1st 7 days after randomizationSepsis workup defined as one or more of CBC, CRP, Procalcitonin, blood culture during 1st 7 days of life
Need for sepsis workup during 1st 30 days after randomizationDuring 1st 30 days after randomizationSepsis workup defined as one or more of CBC, CRP, Procalcitonin, blood culture during 1st 30 days of life
Need for sepsis workup during hospital stayDuring hospital stay upto 100 daysSepsis workup defined as one or more of CBC, CRP, Procalcitonin, blood culture during hospital stay, with the period of observation during hospital stay being capped at 100 days
Cumulative duration of antibiotic therapy during 1st 7 days after randomizationDuring 1st 7 days after randomizationCumulative duration of antibiotic therapy during the 1st 7 days, which may include the sum of the durations of multiple courses of antibiotics, either in continuation or discontinuous. If any course of antibiotics continues beyond the 1st 7 days after randomization, only that portion of the antibiotic course would be included until the 1st 7 days after randomization.
Cumulative duration of antibiotic therapy during 1st 72 hrs after randomizationDuring 1st 72 hours after randomizationCumulative measure of antibiotics therapy during the 1st 72 hours
Cumulative duration of antibiotic therapy during hospital stayDuring hospital stay upto 100 days after randomizationCumulative measure of antibiotics therapy during hospital stay, with the period of observation during hospital stay capped at 100 days
Duration of hospitalizationUpto 100 daysFull length of hospital stay, with the period capped at 100 days
Episodes of healthcare associated infection during hospital stay.From after 72 hours until 100 days during hospital stayDefined as any episode of culture positive sepsis with onset after 72 hours of life or any episode of culture-positive sepsis if baseline blood culture was sterile, with the period of observation during hospital stay capped at 100 days
Adverse effects until day 30 after randomizationDuring 30 days after randomizationAdverse effects will be recorded as per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.
Serious adverse effects until day 30 after randomizationDuring 30 days after randomizationSerious adverse effects will be recorded as per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.
Clinical sepsis during hospital stayDuring hospital stay upto 100 daysEpisodes of clinical EONS (as per definition from a repertoire of clinical signs with normal lab parameters) during hospital stay, with maximum duration of observation during hospital stay being capped at 100 days after randomization
All-cause Mortality within 1st 7 days after randomizationDuring 1st 7 days after randomizationMortality due to any cause

Countries

India

Contacts

Primary ContactSourabh Dutta, MD, Ph.D
sourabhdutta1@gmail.com+91-1722755313
Backup ContactSajan Saini, MD, DM
sajansaini1@gmail.com+91-1722756264

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026